SLRX Salarius Pharmaceuticals Inc

FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE...

HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced plans to explore strategic ...

The trial will assess the safety and preliminary efficacy of Salarius novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a gene signature to identify patients that are potentially sensitized to SP-3164 treatment and may be ...

Salarius Pharmaceuticals (NASDAQ:SLRX Get Rating) and Orgenesis (NASDAQ:ORGS Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, ...

New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomideHOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX Get Rating) Research analysts at Diamond Equity raised their Q2 2023 EPS estimates for Salarius Pharmaceuticals in a note issued to investors on Monday, May 15th. Diamond Equity analyst H. Diamond now forecasts that the company will post ...